Metabolic Memory in Diabetic Foot Syndrome (DFS): Epigenetic Changes of the Expression of Micro-rnas and Single Nucleotide Polymorphisms (SNPS) Frequency in a Cohort of Diabetic Patients With and Without Foot Ulceration and Correlation With Indices of Endothelial and Adipo-inflammatory Dysfunction
Author:
Cuore Alessandro Del1, Pipitone Rosaria Maria2, Casuccio Alessandra2, Mazzola Marco1, Puleo Maria Grazia1, Pacinella Gaetano1, Riolo Renata1, Maida Carlo1, Chiara Tiziana2, Raimondo Domenico2, Zito Rossella2, Lupo Giulia2, Agnello Luisa2, Ciaccio Marcello2, Grimaudo Stefania2, Tuttolomondo Antonino2
Affiliation:
1. Policlinico "P. Giaccone" 2. University of Palermo
Abstract
Abstract
Diabetic foot is a significant cause of morbidity in diabetic patients, with a rate that is approximately twice that of patients without foot ulcers. There has been much debate in the literature about the role of genetics, particularly epigenetic modifications, in the genesis of the diabetic foot. “Metabolic memory” are all those epigenetic changes induced by chronic hyperglycaemia, despite correction of the glycaemic values themselves. Moreover, these epigenetic modifications would appear to perpetuate the damage caused by persistently elevated glucose levels even in its absence, acting at various levels, mostly affecting the molecular processes of diabetic ulcer healing. Our study aimed to analyze the epigenetic changes induced on miRNAs 126, 305, and 217 and on SNPs of inflammatory molecules, such as IL-6, TNF-alpha, and pro-angiogenic molecules, such as ENOS, VEGF and HIF-1alpha with endothelial dysfunction, assessed noninvasively by RHI and with serum levels of inflammatory molecules and adipokines in a population of people with diabetes with and without lower limb ulcer. Between March 2021 and June 2022, 110 patients were enrolled to the study: 50 diabetic patients with diabetic foot injuries, 40 diabetic patients without ulcerative complications and 20 non-diabetic patients, as control group. Diabetic subjects with lower limb ulcerative lesion exhibited higher values of inflammatory cytokines, such as VEGF (191.40 ± 200 pg/mL vs 98.27 ± 56.92 pg/mL vs 71.01 ± 52.96 pg/mL p = 0.22), HIF-1alpha (40.18 ± 10.80 ng/mL vs 33.50 ± 6.16 ng/mL vs 33.85 ± 6.84 ng/mL p = 0, 10), and Gremlin-1 (1.72 ± 0.512 ng/mL vs 1.31 ± 0.21 ng/mL vs 1.11 ± 0.19 ng/mL p < 0.0005). Furthermore, we observed that miR-217-5p and miR-503-5p were respectively 2.19-fold (p < 0.05) and 6.21-fold (p = 0.001) more expressed in diabetic foot patients than in healthy controls (Table 5, Graphic 1). Additionally, diabetic patients without lower limb ulcer complication showed a 2.41-fold (p = 0) and 2.24-fold (p = 0.029) higher expression of miR-217-5p and miR-503-5p, respectively, than healthy controls. Finally, diabetic patients with and without ulcerative complications of the lower limb showed a higher expression of the VEGFC2578A CC polymorphism (p = 0.001) and a lower expression of the VEGFC2578A AC polymorphism (p < 0.005) compared to the healthy control population. We identified a significant increase in Gremlin-1 in patients with diabetic foot and how this inflammatory adipokine is a predictive marker for the diagnosis of diabetic foot. Our results highlighted that patients with diabetic foot show predominant expression of the VEGF C2578A CC polymorphism and reduced expression of the AC allele. Additionally, we found an overexpression of miR-217-5p and miR-503-5p in diabetic patients with and without diabetic foot syndrome. These results align with the licterature, who evidenced the overexpression of miR-217-5p and miR-503-5p in the context of diabetic foot. These epigenetic modifications could therefore be helpful in the early diagnosis of diabetic foot and the treatment of risk factors. However, only further studies will be able to confirm this hypothesis.
Publisher
Research Square Platform LLC
Reference45 articles.
1. Abbott RD, Brand FN, Kannel WB. “Epidemiology of some peripheral arterial findings in diabetic men and women: experiences from the Framingham Study,” The American Jour- nal of Medicine, vol. 88, no. 4, pp. 376–81, 1990. 2. Cardiovas-cular risk profile and morbidity in subjects affected by type 2 diabetes mellitus with and without diabetic foot;Pinto A;Metabolism,2008 3. Tuttolomondo A, La Placa S, Di Raimondo D et al. “Adiponectin, resistin and IL-6 plasma levels in subjects with diabetic foot and possible correlations with clinical variables and cardiovascular co-morbidity,” Cardiovasc Diabetol, vol. 9, article 50, 2010. 4. Tuttolomondo A, Casuccio A, Guercio G, Maida C, Del Cuore A, Di Raimondo D, Simonetta I, Di Bona D, Pecoraro R, Della Corte V, Gulotta E, Gulotta G, Pinto A. Arterial stiffness, endothelial and cognitive function in subjects with type 2 diabetes in accordance with absence or presence of diabetic foot syndrome. Cardiovasc Diabetol 2017 Jan 6;16(1):2. doi: 10.1186/s12933-016-0483-5. 5. Leeper NJ, Cooke JP. MicroRNA and mechanisms of impaired angiogenesis in diabetes mellitus. Circulation. 2011 Jan 25;123(3):236-8. doi: 10.1161/CIRCULATIONAHA.110.003855. Epub 2011 Jan 10. PMID: 21220736; PMCID: PMC3180955.
|
|